Equillium Stock Today
| EQ Stock | USD 0.75 0.03 3.85% |
PerformanceModest
| Odds Of DistressLow
|
Equillium is selling at 0.75 as of the 15th of March 2025; that is 3.85 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.75. Equillium has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 15th of December 2024 and ending today, the 15th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of October 2018 | Category Healthcare | Classification Health Care |
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. The company has 35.43 M outstanding shares of which 672.34 K shares are currently sold short in the market by investors with about 0.19 days to cover all shorted shares. More on Equillium
Moving together with Equillium Stock
Moving against Equillium Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Equillium Stock Highlights
| Chairman of the Board, CEO | Daniel Bradbury | ||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsEquillium can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Equillium's financial leverage. It provides some insight into what part of Equillium's total assets is financed by creditors.
| |||||
Equillium (EQ) is traded on NASDAQ Exchange in USA. It is located in 2223 Avenida De La Playa, La Jolla, CA, United States, 92037 and employs 45 people. Equillium is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a market capitalization of 26.75 M. Equillium is active under Biotechnology sector as part of Health Care industry. The entity has 35.43 M outstanding shares of which 672.34 K shares are currently sold short in the market by investors with about 0.19 days to cover all shorted shares.
Equillium reports about 57.56 M in cash with (21.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Equillium Probability Of Bankruptcy
Ownership AllocationEquillium holds a total of 35.43 Million outstanding shares. Equillium retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Equillium Ownership Details
Equillium Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2024-12-31 | 35 K | |
| Commonwealth Equity Services Inc | 2024-12-31 | 25 K | |
| Jane Street Group Llc | 2024-12-31 | 19.8 K | |
| Ubs Group Ag | 2024-12-31 | 17.3 K | |
| Virtu Financial Llc | 2024-12-31 | 15.7 K | |
| Two Sigma Securities, Llc | 2024-12-31 | 13.5 K | |
| Ci Private Wealth Llc | 2024-12-31 | 11 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 6.9 K | |
| Tower Research Capital Llc | 2024-12-31 | 6 K | |
| Decheng Capital Llc | 2024-12-31 | 4.4 M | |
| Takeda Pharmaceutical Co Ltd | 2024-12-31 | 1.8 M |
Equillium Historical Income Statement
Equillium Stock Against Markets
Equillium Corporate Management
| Jason Keyes | Chief Officer | Profile | |
| Matthew Ritter | Senior Development | Profile | |
| Penny Tom | Principal Officer | Profile | |
| Maple MD | Chief Officer | Profile | |
| Krishna MD | Consultant | Profile |
Additional Tools for Equillium Stock Analysis
When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.